Next Article in Journal
Six-Month Chronic Toxicity Study of Tamarind Pulp (Tamarindus indica L.) Water Extract
Previous Article in Journal
Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application
Article Menu

Export Article

Open AccessArticle
Sci. Pharm. 2017, 85(1), 9; doi:10.3390/scipharm85010009

Serum Cystatin C as a Biomarker in Diffuse Large B-Cell Lymphoma

1
Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt
2
Oncology Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
*
Author to whom correspondence should be addressed.
Academic Editor: Gernot Eller
Received: 22 October 2016 / Revised: 28 February 2017 / Accepted: 28 February 2017 / Published: 8 March 2017
View Full-Text   |   Download PDF [2492 KB, uploaded 8 March 2017]   |  

Abstract

Elevated serum levels of cystatin C are found to be related to poor outcome and metastatic potential of some malignant disorders. To evaluate the clinical prominence of serum cystatin C in diffuse large B-cell lymphoma (DLBCL), blood samples were obtained from 58 patients at the time of diagnosis and paired blood samples were obtained from 22 patients at the time of remission. Also, serum cystatin C level was measured in matched healthy controls. Serum cystatin C levels were significantly more elevated in DLBCL patients than in controls (p < 0.0001). Furthermore, paired-sample analysis revealed that pretreatment cystatin C levels were reduced significantly in patients who achieved remission after therapy (p = 0.016). High serum cystatin C levels were correlated with age over 60 years (p = 0.049), extra-nodal involvement (p = 0.005) and with high serum lactate dehydrogenase (LDH) (p < 0.013). Elevated serum cystatin C levels were associated with extra-nodal involvement and they were significantly reduced to normal range after the remission. However, Kaplan–Meier curves revealed no survival difference in the pretreatment serum cystatin C levels. Therefore, serum cystatin C may be a novel biomarker that reflects tumor burden in DLBCL but bears no prognostic significance regarding survival. View Full-Text
Keywords: diffuse large B-cell lymphoma; cystatin C; survival; extra-nodal involvement diffuse large B-cell lymphoma; cystatin C; survival; extra-nodal involvement
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

  • Externally hosted supplementary file 1
    Doi: scipharm-159925
    Description: scipharm-159925

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Hammouda, N.E.; Salah El-Din, M.A.; El-Shishtawy, M.M.; El-Gayar, A.M. Serum Cystatin C as a Biomarker in Diffuse Large B-Cell Lymphoma. Sci. Pharm. 2017, 85, 9.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top